NLRP3 inflammasome is associated with the response to IFN-β in patients with multiple sclerosis
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Evidence exists for a potential modulation of inflammasome activity by interferon beta. Here, we investigated the roles of inflammasomes [absent in melanoma 2 (AIM2); NLR family, CARD domain containing 4 (NLRC4); NLR family, pyrin domain containing 1 and 3 (NLRP1 and NLRP3)] and related cytokines (IL1B, IL10, IL18) in the response to interferon beta in patients with relapsing-remitting multiple sclerosis. Ninety-seven patients treated with interferon beta were classified into responders and non-responders according to clinical criteria after 24 months and clinical-radiological criteria after 12 months of treatment. Messenger RNA expression levels of inflammasomes and cytokines were determined by real-time polymerase chain reaction in peripheral blood mononuclear cells collected before treatment with interferon beta. In a subgroup of patients, NLRP3 and IL1B expression was also determined after 3 months (n = 32) and 12 months (n = 20) of interferon beta treatment. A polymorphism located in the NLRP3 gene, rs35829419, was genotyped in 789 multiple sclerosis patients treated with interferon beta. Baseline mRNA expression levels for NLRP3 and IL1B were increased in peripheral blood mononuclear cells from non-responders compared to responders classified according to clinical criteria after 24 months (P = 0.02 and P = 0.001, respectively). No significant differences were observed for other inflammasomes and related cytokines. Differences in NLRP3 and IL1B expression remained significant following a clinical-radiological classification after 12 months (P = 0.007 and P = 0.02, respectively). After treatment with interferon beta, NLRP3 and IL1B expression was increased in responders but unchanged in non-responders. A trend for association was observed between rs35829419 and interferon beta response (pM-H = 0.08). These results point to a role of the NLRP3 inflammasome and its related cytokine IL1B in the response to interferon beta in patients with relapsing-remitting multiple sclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Molecular Mechanism of NLRP3 Inflammasome Activation
Jin, C., & Flavell, R. A. (2010) · Journal of Clinical Immunology · doi:10.1007/s10875-010-9440-3 · Cited by 440 · cited 1×
“They are known to sense a wide range of stimuli including bacteria, fungi, extracellular ATP, amyloid-b and uric acid, as well as various environmental irritants, such as silica, asbestos and alum (Jin and Flavell, 2010).”
BackgroundGris, D., Ye, Z., Iocca, H. A., Wen, H., Craven, R. R., Gris, P., Huang, M., Schneider, M., Miller, S. D., & Ting, J. P.-Y. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0904145 · Cited by 429 · cited 3×
“…the roles of inflammasomes [absent in melanoma 2 (AIM2); NLR family, CARD domain containing 4 (NLRC4); NLR family, pyrin domain containing 1 and 3 (NLRP1 and NLRP3)] and related cytokines (IL1B, IL10, IL18) in the response to interferon beta in patients with relapsing-remitting multiple sclerosis.”
BackgroundResultJha, S., Srivastava, S. Y., Brickey, W. J., Iocca, H., Toews, A., Morrison, J. P., Chen, V. S., Gris, D., Matsushima, G. K., & Ting, J. P.-Y. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4088-10.2010 · Cited by 310 · cited 2×
“Similarly, in a cuprizone-induced demyelination model Nlrp3 gene expression was significantly upregulated and Nlrp3-deficient mice showed delayed demyelination and oligodendrocyte loss (Jha et al., 2010).”
BackgroundMethod
Cited by
Targeting the NLRP3 inflammasome in inflammatory diseases
Mangan, M. S. J., Olhava, E. J., Roush, W. R., Seidel, H. M., Glick, G. D., & Latz, E. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.97 · Cited by 1,885
NLRP3 inflammasome and its inhibitors: a review
Shao, B.-Z., Xu, Z.-Q., Han, B.-Z., Su, D.-F., & Liu, C. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00262 · Cited by 836
“Malhotra et al. (2015) classified 97 patients with multiple sclerosis into those who responded to IFN-β therapy and those who did not, based on clinico-radiological criteria at 12 and 24 months of treatment.”
BackgroundMethodMartínez, G. J., Celermajer, D. S., & Patel, S. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.12.027 · Cited by 342
The pathogenic role of the inflammasome in neurodegenerative diseases
Freeman, L. C., & Ting, J. P. ‐. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13217 · Cited by 276
Role of inflammasomes in multiple sclerosis and their potential as therapeutic targets
Govindarajan, V., de Rivero Vaccari, J. P., & Keane, R. W. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01944-9 · Cited by 110
Metadata
- Authors
- Malhotra, S., Río, J., Urcelay, E., Nurtdinov, R., Bustamante, M. F., Fernández, O., Oliver, B., Zettl, U., Brassat, D., Killestein, J., Lechner-Scott, J., Drulovic, J., Chan, A., Martinelli-Boneschi, F., García-Merino, A., Montalban, X., & Comabella, M.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-01-12
- Volume
- 138
- Issue
- 3
- Pages
- 644-652
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2026694335
- Cited by
- 111
- References
- 4
- FWCI
- 9.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: NLRP3 inflammasome is associated with the response to IFN-β in patients with multiple sclerosis. https://app.cochat.ai/papers/10.1093/brain/awu388
- The paper
- Malhotra, S., Río, J., Urcelay, E., Nurtdinov, R., Bustamante, M. F., Fernández, O., Oliver, B., Zettl, U., Brassat, D., Killestein, J., Lechner-Scott, J., Drulovic, J., Chan, A., Martinelli-Boneschi, F., García-Merino, A., Montalban, X., & Comabella, M. (2015). NLRP3 inflammasome is associated with the response to IFN-β in patients with multiple sclerosis. Brain. https://doi.org/10.1093/brain/awu388
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.